Schroder Investment Management Group grew its position in Repligen Co. (NASDAQ:RGEN) by 3.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 478,243 shares of the biotechnology company’s stock after purchasing an additional 17,352 shares during the period. Schroder Investment Management Group’s holdings in Repligen were worth $17,351,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Palisade Capital Management LLC NJ boosted its holdings in shares of Repligen by 4.5% during the third quarter. Palisade Capital Management LLC NJ now owns 658,979 shares of the biotechnology company’s stock worth $25,252,000 after purchasing an additional 28,646 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Repligen during the third quarter worth approximately $3,349,000. Vanguard Group Inc. boosted its holdings in shares of Repligen by 9.7% during the second quarter. Vanguard Group Inc. now owns 1,984,393 shares of the biotechnology company’s stock worth $82,233,000 after purchasing an additional 175,191 shares during the period. Boston Advisors LLC boosted its holdings in shares of Repligen by 17.9% during the third quarter. Boston Advisors LLC now owns 139,483 shares of the biotechnology company’s stock worth $5,345,000 after purchasing an additional 21,185 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its holdings in shares of Repligen by 78.0% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 16,206 shares of the biotechnology company’s stock worth $620,000 after purchasing an additional 7,100 shares during the period. Institutional investors own 84.32% of the company’s stock.
In other news, VP Howard Benjamin sold 12,729 shares of Repligen stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $35.34, for a total value of $449,842.86. Following the transaction, the vice president now owns 36,554 shares of the company’s stock, valued at $1,291,818.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Anthony Hunt sold 8,970 shares of Repligen stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $35.95, for a total transaction of $322,471.50. Following the completion of the transaction, the chief executive officer now directly owns 83,613 shares in the company, valued at approximately $3,005,887.35. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.
Shares of Repligen Co. (RGEN) opened at $35.37 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.63 and a quick ratio of 8.08. The stock has a market cap of $1,541.72, a P/E ratio of 49.82, a price-to-earnings-growth ratio of 2.03 and a beta of 0.91. Repligen Co. has a one year low of $29.56 and a one year high of $46.81.
Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, February 22nd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.08. The firm had revenue of $41.60 million during the quarter, compared to analysts’ expectations of $41.13 million. Repligen had a net margin of 20.08% and a return on equity of 7.08%. The company’s revenue was up 62.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.08 earnings per share. equities research analysts predict that Repligen Co. will post 0.7 EPS for the current fiscal year.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.